Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China

Eur Respir J. 2021 Mar 11;57(3):2003463. doi: 10.1183/13993003.03463-2020. Print 2021 Mar.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antitubercular Agents / therapeutic use
  • China
  • Fluoroquinolones
  • Humans
  • Levofloxacin
  • Microbial Sensitivity Tests
  • Moxifloxacin
  • Mycobacterium tuberculosis*
  • Ofloxacin
  • Pharmaceutical Preparations*
  • Prospective Studies
  • Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

  • Antitubercular Agents
  • Fluoroquinolones
  • Pharmaceutical Preparations
  • Levofloxacin
  • Ofloxacin
  • Moxifloxacin

Associated data

  • ClinicalTrials.gov/NCT02816931